AA
AIMT

ALPS Advisors’s Aimmune Therapeutics AIMT Stock Holding History

ALPS Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-103,482
Closed -$2.82M – 981
2018
Q3 		$2.82M Buy
103,482
+19,414
+23% +$549K 0.02% 210
2018
Q2 		$2.26M Buy
84,068
+8,168
+11% +$250K 0.01% 220
2018
Q1 		$2.42M Buy
75,900
+19,538
+35% +$688K 0.02% 196
2017
Q4 		$2.13M Buy
56,362
+6,594
+13% +$213K 0.01% 192
2017
Q3 		$1.23M Buy
49,768
+4,412
+10% +$95.1K 0.01% 223
2017
Q2 		$933K Buy
45,356
+2,302
+5% +$43.9K 0.01% 232
2017
Q1 		$936K Buy
43,054
+2,324
+6% +$47.7K 0.01% 222
2016
Q4 		$833K Sell
40,730
-13,137
-24% -$269K 0.01% 232
2016
Q3 		$808K Sell
53,867
-5,484
-9% -$74K 0.01% 230
2016
Q2 		$642K Buy
59,351
+11,837
+25% +$161K 0.01% 224
2016
Q1 		$644K Sell
47,514
-8,143
-15% -$127K 0.01% 204
2015
Q4 		$1.03M Buy
+55,657
New +$1.03M 0.01% 216

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ALPS Advisors's AIMT Position: Q4 2018 in Review

ALPS Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2018, closing a stake of 103,482 shares — an estimated $2.82M sold.

ALPS Advisors first reported a position in AIMT in Q4 2015 and held it in 12 quarters. The position peaked at $2.82M in Q3 2018. 132 funds tracked by Wall St. Rank hold AIMT as of Q4 2018.

  • ALPS Advisors reported no remaining Aimmune Therapeutics position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 103,482 Aimmune Therapeutics shares in Q4 2018, an estimated $2.82M.
  • ALPS Advisors first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 12 quarters.
  • ALPS Advisors's Aimmune Therapeutics position peaked at $2.82M in Q3 2018.
  • 132 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.